Table 2.
Univariate associations between explicative factors and ABPA in people with cystic fibrosis from the French CF Registry.
| Odds ratio | 95% confidence interval | P-value | |
|---|---|---|---|
| CFTR genotypes | |||
| F508del/F508del vs. other/other | 0.87 | [0.60; 1.27] | .4712 |
| F508del/other vs. other/other | 0.98 | [0.68; 1.43] | .9316 |
| Nutritional status, BMI | |||
| BMI (continuous) | 0.93 | [0.88; 0.98] | .0070 |
| Low (<18.5) vs. normal (18.5–24.9) | 1.15 | [0.79; 1.67] | .4532 |
| High (>25) vs. normal (18.5–24.9) | 0.47 | [0.24; 0.93] | .0297 |
| Glucose disorder | |||
| Glucose disorder vs. none | 1.52 | [1.13; 2.05] | .0055 |
| Glucose intolerance vs. none | 1.48 | [1.08; 2.02] | .0147 |
| CF-related diabetes vs. none | 1.68 | [1.11; 2.53] | .0144 |
| Severe CF-liver disease (cirrhosis) | 1.10 | [0.75; 1.61] | .6224 |
| Respiratory status | |||
| ppFEV1 (continuous) | 0.99 | [0.98; 1.00] | .0012 |
| ppFEV1 < 40% vs. ≥ 70% | 1.28 | [0.75; 2.17] | .3675 |
| ppFEV1 40%–70% vs. ≥ 70% | 1.45 | [1.03; 2.04] | .0324 |
| Asthma | 1.60 | [1.24; 2.08] | .0004 |
| Chronic airway colonization | |||
| Pseudomonas aeruginosa colonization vs. none | 1.64 | [1.18; 2.27] | .0030 |
| MRSA colonization vs. none | 2.02 | [0.98; 4.14] | .0559 |
| MSSA colonization vs. none | 1.02 | [0.75; 1.37] | .9090 |
| Burkholderia species colonization vs. none | 1.53 | [0.51; 4.62] | .4490 |
| Achromobacter species colonization vs. none | 0.95 | [0.40; 2.25] | .9136 |
| Stenotrophomonas maltophilia colonization vs. none | 1.50 | [0.61; 3.72] | .3811 |
| Therapy for advanced pulmonary disease | |||
| Any (oxygen or NIV) vs. none | 2.77 | [1.47; 5.24] | .0017 |
| Oxygenotherapy vs. none | 2.27 | [1.04; 4.97] | .0396 |
| NIV vs. none | 2.60 | [1.10; 6.14] | .0300 |
| Number of annual intravenous antibiotic courses | |||
| 1–3 vs. 0 | 2.13 | [1.57; 2.90] | <.0001 |
| >3 vs. 0 | 3.74 | [1.99; 7.04] | <.0001 |
| Long-term inhaled antibiotics | 1.91 | [1.39; 2.62] | <.0001 |
| Long-term inhaled mucolytics | 1.46 | [1.05; 2.04] | .0257 |
| Long-term inhaled corticosteroids | 2.03 | [1.52; 2.73] | <.0001 |
| Long-term oral corticosteroids | 2.48 | [1.35; 4.55] | .0034 |
| Long-term azithromycin | 1.48 | [1.13; 1.96] | .0050 |
| Antifungal treatment | 9.00 | [4.04; 20.03] | <.0001 |
| CFTR modulator therapy | 0.87 | [0.63; 1.20] | .3951 |
Note: Significant P-values are in bold.
CFTR: cystic fibrosis transmembrane conductance regulator, ppFEV1: predicted forced expiratory volume in 1 s, BMI: body mass index, MRSA: Methicillin resistant Staphylococcus aureus MSSA: Methicillin susceptible Staphylococcus aureus, NIV: noninvasive ventilation.